N/A N=299 Evaluation of Spine Surgery Analgesic Pathway
Posterior Spine Surgery
Primary: Quality of Recovery — 109; 109 units on a scale — p=0.92
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=40 A Randomized Controlled Crossover Study Comparing Sugammadex and Placebo
Posterior Cervical Decompression and Fusion
Primary: Changes Motor Evoked Potentials (MEPs) Amplitude at 3 Minutes — 652.9; 20.6; 2153.4; 55 micro volts — p=<0.01
N/A N=24 A Clinical Comparison of 2 Multifocal Toric XR (Extended Range) Contact Lenses
Astigmatism
Primary: Stability — 3.2; 2.9 units on a scale
Phase 2 N=665 Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age
Influenza
Primary: Number of Participants With Immediate Unsolicited Adverse Events (AEs) After Any Vaccination — 0; 0; 1; 0 Participants
Phase 3 N=58 PRecision Interventions for SMoking in the SCCS
Tobacco Use Cessation
Primary: Intervention Feasibility: Ability to Retain Participants — 19; 19; 20; 18 Participants
N/A N=51 INVSENSOR00027 Fall Detection Clinical Performance Study
Healthy
Primary: Sensitivity of INVSENSOR00027's Fall Detection. — 93.9 percentage of falls detected
N/A N=108 Association Between Food/Nutrient Intake and Sleep Quality in Middle Aged and Older Population
Sleep
Primary: Sleep Quality Assessment 1 (GSS) — 3.4; 8.1; 5.2 score on a scale
N/A N=45 Study to Assess the ART Impact on the Brain Outcomes. The ARBRE Study
HIV-1 Infection · Cognitive Impairment
Primary: Change in Global Cognitive Functioning — 0.08; 0.31; 0.25 score on a scale
Phase 3 N=111 A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma
Asthma
Primary: Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) — 23; 7; 32; 1 Participants
Phase 2 N=36 Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Primary: Percent Reduction From Baseline to Week 8 in Frequency of Total Seizures (Normalized to a 4-Week Rate) — 12.6; 0.0 percent reduction of seizures per 4 wks — p=0.5812
Phase 2 N=249 A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis
Ulcerative Colitis
Primary: Induction Period: Percentage of Participants With Clinical Remission at Week 12 — 4.8; 15.9; 22.6; 11.5 percentage of participants
Phase 2 N=150 Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma
Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma
Primary: Recurrence-Free Survival (RFS) — 0.0; 0.0 months — p=0.070
Phase 2 N=103 Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy
Allergic Rhinitis
Primary: Percent Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) (0-1 Hour (hr) Post Peak TNSS) in Response to Post Nasal Allergen Challenge (NAC)…
N/A N=25 Transesophageal Echocardiography (TEE) to Guide and Confirm Epidural Catheters in Pediatric Patients
Epidural Space
Primary: Number of Participants With Successful Epidural Catheter Placement — 17; 3 Participants
Phase 4 N=16 Bioequivalence of Ethylenediamine Dihydrochloride Study
Allergic Contact Dermatitis
Primary: Number of Participants With Positive Reactions to Ethylenediamine Dihydrochloride in MC (Methylcellulose) and Ethylenediamine Dihydrochloride in PVP…